On the morning of September 8, the fourth branch of China Pharmaceutical Congress named “Seminar on Innovative Drug Discovery and Druggability Evaluation” was held on CPU Xuanwumen Campus. The seminar was jointly sponsored by the Pharmaceutical Chemistry Professional Committee of Chinese Pharmaceutical Association (CPA) and the Applied Pharmacology Professional Committee of CPA, and was undertaken by CPU. It was presented in the form of both on-site seminar and online live broadcast. Prof. Chen Kaixian, Academician of Chinese Academy of Sciences, Prof. Wang Guangji, Academician of Chinese Academy of Engineering, and Prof. Hao Haiping, Vice President of CPU, delivered speeches on behalf of the Medicinal Chemistry Professional Committee of CPA, Applied Pharmacology Professional Committee of CPA and China Pharmaceutical University, respectively. The conference was presided over by Prof. Shang Jing and Prof. Xu Yungen from CPU.
Focusing on the theme of Carrying forward the Spirit of Fighting COVID-19 and Promoting the High-Quality Development of Pharmacy, this conference invited Prof. Hao Haiping from CPU, Prof. Chen Zhong from Zhejiang Chinese Medical University, Prof. Luo Xiaodong from Yunnan University, Prof. Li Honglin from East China University of Science and Technology，Prof. Li Su from Sun Yat-sen University Cancer Center and many other experts to deliver wonderful reports.
In his report entitled “Research and Thought on MASH Drug”, Prof. Hao Haiping conducted in-depth analysis of pathogenesis, research progress, discovery of related targets and treatment strategies of fatty liver, which provided new ideas for the development of anti-fatty liver drugs. Prof. Li Honglin delivered a speech named “Discovery of Anti-RNA Virus Candidate Drugs”. He shared his self-built method and software for drug target identification and drug discovery, with which efficient anti-2019-nCOV candidate drug was found and prompted to clinical trials, and some research results have won high attention and praise from international colleagues. The title of Prof. Cheng Zhong’s report was “Analysis of the Pathogenesis of Epilepsy and Its New Drug Target”. He had carried out a lot of solid basic research on the pathogenesis of epilepsy which revealed some new mechanisms; focusing on such new pathogenesis and targets, he then conducted innovative drug research and achieved major progress. Prof. Luo Xiaodong gave the report under the theme of “Creation of New Drug: Natural Indole Alkaloid”. The research team under his lead had carried out long-term research on total alkaloids of leaves of Alstonia scholaris, including quality control of pharmaceutical materials, preparation and purification of active ingredients, activity screening, and Phase IIA clinical trials; based on the good prognosis for pneumonia and bronchitis, this drug was recommended for the treatment of COVID-19. Prof. Li Su address her report “Precision, Target, and Immune--Development and Application of Chemotherapy Drugs”. Short as the time was, the experts’ report presented one wonderful academic feast for the delegates.
Apart from more than 60 delegates participating in the on-site conference, the seminar also attracted a total of 1913 audience from all over the country to watch online. The successful conference would play a positive role in promoting cross-disciplinary integration and inspiring innovative drug research.
